A5055495178- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- HIV/AIDS drug development and treatment
- Liver Disease and Transplantation
- HIV Research and Treatment
- Hepatitis Viruses Studies and Epidemiology
- Viral gastroenteritis research and epidemiology
- HIV-related health complications and treatments
- Systemic Lupus Erythematosus Research
- Renal Transplantation Outcomes and Treatments
- HIV/AIDS Research and Interventions
- Chronic Lymphocytic Leukemia Research
- Monoclonal and Polyclonal Antibodies Research
- Liver Diseases and Immunity
- Organ Transplantation Techniques and Outcomes
- Alcohol Consumption and Health Effects
- Drug-Induced Hepatotoxicity and Protection
- Immune Cell Function and Interaction
- Pancreatitis Pathology and Treatment
- Cannabis and Cannabinoid Research
- Cytomegalovirus and herpesvirus research
- Food Security and Health in Diverse Populations
- HIV, Drug Use, Sexual Risk
- Viral Infectious Diseases and Gene Expression in Insects
University of Cincinnati Medical Center
2016-2025
Harvard University
2004-2025
Massachusetts General Hospital
2023-2025
University of Cincinnati
2015-2024
University of Florida
2023
Sabin Vaccine Institute
2005-2022
Mentor
2019
Hospital Universitario La Paz
2017
Centre For Digestive Diseases
2006-2016
Johns Hopkins Medicine
2013
Chronic hepatitis C virus (HCV) infection is a cause of major complications in persons who are also infected with the human immunodeficiency (HIV). However, treatment HCV such has been associated high rate intolerance and low response. We conducted multicenter, randomized trial comparing peginterferon plus ribavirin interferon for chronic coinfected HIV.A total 66 subjects were randomly assigned to receive 180 microg alfa-2a weekly 48 weeks, 67 6 million IU three times 12 weeks followed by 3...
Hepatitis C virus (HCV) has emerged as an important etiologic agent of liver injury and failure in patients infected with human immunodeficiency (HIV). The prevalence characteristics HCV a representative cohort HIV-infected have not been described. Therefore, sample 1687 was studied; 213-sample subcohort selected by use risk-based sampling from 2 large prospective US Adult AIDS Clinical Trials Group clinical trials. prevalence, RNA level, genotype were determined. weighted overall estimate...
Patients with chronic infection hepatitis C virus (HCV) genotype 1 often need 48 weeks of peginterferon–ribavirin treatment for a sustained virologic response. We designed noninferiority trial (noninferiority margin, −10.5%) to compare rates response among patients receiving two durations.
The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on safety this coinfected human immunodeficiency type 1 (HIV-1).This was an open-label study involving 151 who had not received treatment 52 previously treated patients, all whom were HIV-1. Previously untreated randomly assigned 2:1 ratio to receive either 12 weeks or 8 daclatasvir at standard dose 60 mg daily...
Quantitation of the hepatitis C virus (HCV) provides a powerful epidemiologic and therapeutic method for evaluation infected patients. In this study semiquantitative reverse transcriptase polymerase chain reaction (PCR) is compared with new branched DNA signal amplification methodology. Samples from HCV-infected patients as well human immunodeficiency virus-infected were evaluated. Reverse PCR correlated assay (r = 0.7036, P < 0.05). HCV RNA was found to occur at significantly higher...
Hepatitis C virus (HCV) is a controversial indication for liver transplantation (LT) in human immunodeficiency (HIV)-infected patients because of reportedly poor outcomes. This prospective, multicenter US cohort study compared patient and graft survival 89 HCV/HIV-coinfected 2 control groups: 235 HCV-monoinfected LT controls all transplant recipients who were 65 years old or older. The 3-year rates 60% [95% confidence interval (CI) = 47%-71%] 53% (95% CI 40%-64%) the HCV/HIV 79% 72%-84%) 74%...
Bilirubin, the primary end product of heme catabolism, is a key marker liver and hematological disorders, important cytoprotective properties have been ascribed to this bile pigment. The Third National Health Nutrition Examination Survey, comprehensive assessment health nutrition in United States, was analyzed determine demographics correlates serum bilirubin levels general population. Men women aged 17 older were included weighted analysis, representing total 176,748,462 subjects. mean...
Chinese translation Background: Telaprevir (TVR) plus peginterferon-α2a (PEG-IFN-α2a) and ribavirin substantially increases treatment efficacy for genotype 1 chronic hepatitis C virus (HCV) infection versus PEG-IFN-α2a–ribavirin alone. Its safety in patients with HCV HIV-1 are unknown. Objective: To assess the of TVR to evaluate pharmacokinetics antiretrovirals during coadministration. Design: Phase 2a, randomized, double-blind, placebo-controlled study. (ClinicalTrials.gov: NCT00983853)...
Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in subjects coinfected with HIV. Tenofovir disoproxil fumarate (TDF) adefovir dipivoxil (ADV) are licensed for the treatment HIV-1 HBV infection, respectively, but both have vivo vitro activity against HBV. This study evaluated anti-HBV TDF compared to ADV HIV/HBV-coinfected subjects. ACTG A5127 was a prospective randomized, double-blind, placebo-controlled trial daily 10 mg versus 300 HIV coinfection...
Bilirubin, the primary end product of heme catabolism, is a key marker liver and hematological disorders, important cytoprotective properties have been ascribed to this bile pigment. The Third National Health Nutrition Examination Survey, comprehensive assessment health nutrition in United States, was analyzed determine demographics correlates serum bilirubin levels general population. Men women aged 17 older were included weighted analysis, representing total 176,748,462 subjects. mean...
Background. Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact of TVR-resistant variants, we analyzed samples from patients in phase 3 trials determine frequency and retention variants who did not achieve sustained virologic response (SVR).
Once-daily glecaprevir coformulated with pibrentasvir (glecaprevir/pibrentasvir) demonstrated high rates of sustained virologic response 12 weeks after treatment (SVR12) in patients hepatitis C virus (HCV) genotype 1–6 infection. This phase 3 study evaluated the efficacy and safety glecaprevir/pibrentasvir chronic HCV human immunodeficiency type 1 (HIV-1) coinfection, including compensated cirrhosis. EXPEDITION-2 was a 3, multicenter, open-label evaluating (300 mg/120 mg)...
Hepatitis B virus (HBV) continues to cause significant morbidity and mortality in the United States. Current guidelines suggest screening populations with a prevalence of ≥2%. Our objective was determine whether this threshold is cost-effective lower-prevalence might also be cost-effective.We developed Markov state transition model examine asymptomatic outpatients The base case 35-year-old man living region an HBV infection 2%. Interventions (versus no screening) included for surface antigen...
Breakthroughs in hepatitis C virus (HCV) treatment and rising rates of intravenous drug use have led to an increase the number organ donors who are HCV antibody-positive but serum nucleic acid test (NAT)-negative. The risk transmission from liver grafts these recipients is unknown. To estimate incidence transmission, we prospectively followed 26 consecutive antibody-negative (n = 25) or NAT-negative 1) transplant received a graft were between March 2016 2017. was considered occurred if...
Lamivudine is a nucleoside analog with activity against human immunodeficiency virus (HIV) and hepatitis B (HBV). Patients coinfected HIV HBV may have flares when lamivudine therapy discontinued or resistance of to emerges. This retrospective, descriptive study conducted in three tertiary care medical centers describes patients type 1 who presented spectrum clinical subclinical hepatitic responses withdrawal resistance. One patient had fulminant hepatic failure second was more efficacious...
Objectives: The impact of highly active antiretroviral therapy (HAART) on hepatitis C virus (HCV) is unknown. We analysed changes in HCV RNA and the frequency hepatotoxicity co-infected patient enrolling AIDS Clinical Trials Group trials, determined whether impairs successful immune reconstitution these populations. Design/methods: In a prospective analysis patients completing at least 16 weeks HAART four with available stored plasma from two other completed was measured baseline to week 48....
Alanine aminotransferase is an enzyme produced mainly in the liver. When serum activity measured, it provides a marker of hepatic disease. This review explores biochemistry and laboratory analysis alanine terms its significance human health Cut-off levels that define abnormality are rather arbitrary this decreases specificity test apparently healthy patients. A small, but important, group patients with have underlying liver disease may be treatable. Most can diagnosed based on history,...
An evaluation of the US Food and Drug Administration's Adverse Event Reporting System identified that patients coinfected with human immunodeficiency virus chronic hepatitis C who were treated a regimen ribavirin didanosine, or without stavudine, at increased risk for events associated mitochondrial toxicity, including fatal hepatic failure, peripheral neuropathy, pancreatitis, symptomatic hyperlactatemia/lactic acidosis. In response, product labels didanosine have been revised to caution...